Literature DB >> 11059990

Future therapeutic targets in mood disorders: the glucocorticoid receptor.

R McQuade1, A H Young.   

Abstract

BACKGROUND: The hypercortisolaemia and dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis associated with mood disorders have been attributed to a breakdown in the glucocorticoid-receptor-mediated negative feedback mechanism regulating HPA activity. Reinstating normal feedback may be therapeutic in mood disorders. AIMS: To review the evidence for the involvement of the glucocorticoid receptor in the pathogenesis and treatment of mood disorders.
METHOD: Medline and hand searches were carried out, selecting literature relevant to psychiatrists and psychopharmacologists.
RESULTS: A dysfunction in glucocorticoid receptors is integral to the HPA abnormalities of mood disorders. Antidepressant and mood-stabilising drugs can up-regulate glucocorticoid receptors, restoring glucocorticoid function. Preliminary clinical studies targeting the glucocorticoid receptor are encouraging.
CONCLUSIONS: Drugs designed specifically to up-regulate glucocorticoid receptors may be integral to future strategies in treating mood disorders.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11059990     DOI: 10.1192/bjp.177.5.390

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  32 in total

1.  The future of antidepressant pharmacotherapy.

Authors:  David Baldwin; Chris Thompson
Journal:  World Psychiatry       Date:  2003-02       Impact factor: 49.548

Review 2.  Sex differences in psychopathology: of gonads, adrenals and mental illness.

Authors:  Matia B Solomon; James P Herman
Journal:  Physiol Behav       Date:  2009-03-09

3.  Coping and glucocorticoid receptor regulation by stress inoculation.

Authors:  Alex G Lee; Christine L Buckmaster; Esther Yi; Alan F Schatzberg; David M Lyons
Journal:  Psychoneuroendocrinology       Date:  2014-08-01       Impact factor: 4.905

4.  Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response.

Authors:  Karen Hodgson; Shaista Jeelani Mufti; Rudolf Uher; Peter McGuffin
Journal:  Genome Med       Date:  2012-06-27       Impact factor: 11.117

5.  Chronic social defeat downregulates the 5-HT1A receptor but not Freud-1 or NUDR in the rat prefrontal cortex.

Authors:  Niamh Kieran; Xiao-Ming Ou; Abiye H Iyo
Journal:  Neurosci Lett       Date:  2009-12-18       Impact factor: 3.046

Review 6.  Future antidepressants: what is in the pipeline and what is missing?

Authors:  Fokko J Bosker; Ben H C Westerink; Thomas I F H Cremers; Marjolein Gerrits; Marieke G C van der Hart; Sjoukje D Kuipers; Gieta van der Pompe; Gert J ter Horst; Johan A den Boer; Jakob Korf
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 7.  Update on stress and depression: the role of the hypothalamic-pituitary-adrenal (HPA) axis.

Authors:  Andrea de Abreu Feijó de Mello; Marcelo Feijó de Mello; Linda L Carpenter; Lawrence H Price
Journal:  Braz J Psychiatry       Date:  2004-01-15       Impact factor: 2.697

8.  Acute stress and chronic stress change brain-derived neurotrophic factor (BDNF) and tyrosine kinase-coupled receptor (TrkB) expression in both young and aged rat hippocampus.

Authors:  Shou-Sen Shi; Shu-Hong Shao; Bang-Ping Yuan; Fang Pan; Zun-Ling Li
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

9.  Glucocorticoid receptor dysfunction: consequences for the pathophysiology and treatment of mood disorders.

Authors:  Aju Abraham; Stuart Watson; Allan H Young
Journal:  Indian J Psychiatry       Date:  2003-04       Impact factor: 1.759

10.  Crossroads of corticotropin releasing hormone, corticosteroids and monoamines. About a biological interface between stress and depression.

Authors:  H. M. Van Praag
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.